Conference day one: Tuesday 31st January

Conference day one: Tuesday 31st January ›

Conference day two: Wednesday 1st February ›

Conference day three: Thursday 2nd February ›

last modified: 20 January '12

Please enable javascript to see more information on speakers

Leadership

8am

Registration and coffee

8.50am

Chairman’s opening remarks

Mr Bernard Munos

Bernard Munos is the founder of the InnoThink Center for Research in Biomedical Innovation, which was created to translate innovation research into better evidence-based business models for the pharmaceutical industry and its stakeholders. Before...

more..

› Mr Bernard Munos, Founder, InnoThink

Creating a company culture to foster innovation

9am

Innovating innovation in pharma: building a new approach to R&D collaboration

Mr. Ellis Rubinstein

Ellis Rubinstein is an innovator and change agent. As a science journalist, his work merited 3 National Magazine Awards, the Pulitzer Prizes of the American periodicals industry. As an editor at Newsweek, the journal Science, Rubinstein increased...

more..

Engaging in novel partnerships with academia, industry and corporate players
Identifying the game changing ideas through crowd-sourcing and collaboration

› Mr. Ellis Rubinstein, President and CEO, The New York Academy of Sciences

9.25am

Encouraging a scientific ecosystem to improve product development

Dr Jeffrey Kralstein at World Pharma Innovation Congress USA

Understanding how to improve the R&D process by balancing flexibility with quality control
Thinking outside the box to create new methods for discovery and development

› Dr Jeffrey Kralstein, Vice President & Global Head, Clinical Policy & Scientific Excellence, Chief Medical Office, Novartis

9.50am

Panel session: the culture of inventive business

Mr. Ellis Rubinstein

more..

Dr. Neil Bodick

Dr. Bodick is a founder of Flexion Therapeutics, where he has served as Chief Medical Officer for the last four years. Previously, he was the founder and Chief Medical Officer of Chorus, an autonomous early-phase drug development accelerator within...

more..

Encouraging a creative environment to foster innovation
Inspiring the office: best practices to motivate beyond the basic 9-to-5
Improving employee satisfaction for collaborative company growth

› Mr. Ellis Rubinstein, President and CEO, The New York Academy of Sciences
› Dr. Neil Bodick, Founder and Chief Medical Officer, Flexion Therapeutics
› Dr Jeffrey Kralstein, Vice President & Global Head, Clinical Policy & Scientific Excellence, Chief Medical Office, Novartis

10.25am

Speed Networking

Establish new relationships in one powerful, 'quickfire' speed networking session. Be sure to bring plenty of business cards.

10.55am

Morning coffee break

Innovation-nation: learning from cross-sector leaders

11.25am

Incentivizing innovation that matters through reward systems

Ms. Katherine Holland

Katherine Holland brings more than thirty years of global leadership, expertise, industry insight and client experience to her current position as IBM’s General Manager, Global Life Sciences Industry. She leads the world wide strategy, solutions...

more..

Offering prizes for finding answers to IBM internal questions
Keeping focused on driving innovation in IBM

› Ms. Katherine Holland, Global General Manager, Life Sciences, IBM

Biotech Investment Showcase

11.50am

First-in-Class therapeutics for wound healing and inflammation

Grove Matsuoka at World Pharma Innovation Congress USA

New target, drug, and mechanism of action
Meeting a large, unmet medical need
Demonstrating human proof-of-concept and target protein over-expression

› Grove Matsuoka, Senior Vice President, Commercialization, CoDa Therapeutics, Inc.

12.10pm

Versatile nanodelivery platform for efficient targeted delivery of macromolecular oncology payloads

Dr. Matthew J. Giacalone at World Pharma Innovation Congress USA

Overcoming Inefficient cytosolic delivery for macromolecular payloads in cancer therapeutics
Deliver macromolecular payloads with bacterial minicells
Mining the platform for products: a one-two punch against tumor and tumor vasculature

› Dr. Matthew J. Giacalone, Director of Business Development, Vaxiion Therapeutics, Inc.

12.30pm

De-risking clinical development for diseases with unmet medical need

Mr. Jess Rabourn at World Pharma Innovation Congress USA

Addressing financial risk-reward asymmetry
Platform for in-licensing and clinically developing existing therapeutics

› Mr. Jess Rabourn, Chief Executive Officer, PCUT BioPartners, Inc.

12.50pm

Networking lunch

Applying corporate innovation models to the pharmaceutical industry

1.50pm

Unveiling the truth: comparing a closed-innovation past with open innovation

Dr. Henry Chesbrough

Henry Chesbrough is Executive Director of the Center for Open Innovation at the Haas School of Business at UC Berkeley. Previously, he was an assistant professor of business administration, and the Class of 1961 Fellow at the Harvard Business...

more..

Moving beyond the blockbuster mentality for sustainable drug development
Balancing strategic insights with collaborative discussion
Allocating intellectual property to advance scientific knowledge

› Dr. Henry Chesbrough, Executive Director, University of California, Berkely-Haas School of Business

2.15pm

How to use the tools necessary for implementing an open innovation model

Mr. John Wilbanks

John Wilbanks works on open content, open data, and open innovation systems in the life sciences and sustainability. He has worked at Creative Commons, the Berkman Center for Internet & Society at Harvard University, MIT’s Computer Science and...

more..

Addressing challenges of IP regulation for open innovation discovery
Understanding different innovation models for therapeutic development
Increasing efficiency with new platforms to access information

› Mr. John Wilbanks, Senior Fellow, Science Commons

2.40pm

Innovation by design: directing Innovation to what matters

Mike Rea

Mike has worked in global pharma for over twenty years, and is a recognized industry leader, named as The Change Maker in the PharmaVoice 100 Most Inspiring Individuals in Healthcare in 2011. Since founding product design company IDEA Pharma, Mike...

more..

Understanding opportunity (and innovation risk) that exists between molecule and product
Productive Innovation: measuring innovation in pharma (by something that matters)
The beginning of the end of blockbusters, or the end of the beginning?

› Mike Rea, CEO, IDEAPharma

3.05pm

Panel: delivering ideas to create something from the ground up

Ms. Katherine Holland

more..

Mr. John Wilbanks

more..

Dr. Henry Chesbrough

more..

Stepping outside the boundaries of the expected
Combining creativity with strong business acumen for ultimate success
Maximizing company strengths when embracing unfamiliar terrain

3.50pm

Creativity, innovation and how portfolio management can support them

Florian Jehle

Florian Jehle is a Principal with Catenion and lives in Berlin Florian started his consulting career in 2002 and joined Catenion in 2005. Florian has worked on multiple projects for many pharmaceutical, medical products and diagnostics companies. He ...

more..

Creativity, serendipity - breakthrough and incremental innovation
Evolving roles of portfolio management from managed research to open innovation and recombinant innovation operating models

› Florian Jehle, , Catenion

4.20pm

Afternoon coffee break

Maintaining motivation: keeping the end in mind

4.50pm

The direct link: from patient advocacy to product development

Dr. Robert J. Beall

Dr. Robert J. Beall has been with the Cystic Fibrosis Foundation for over 30 years. He began his tenure at the CF Foundation as Executive Vice President for Medical Affairs, and for the past 16 years he has served as President and Chief Executive...

more..

Establishing business roots from proactive patient demand
Motivating scientific progress: how to address daily management

› Dr. Robert J. Beall, President and CEO, Cystic Fibrosis Foundation

5.15pm

Industry alliances: holding the reins in a new age of therapeutic development

Mr. Chester Davis

Chester “Chip” Davis, Jr. currently serves as Executive Vice President for Advocacy at PhRMA. In this role Davis is responsible for leading and managing PhRMA’s federal, state and international government relations and advocacy efforts. A veteran...

more..